Literature DB >> 15043889

Keloid formation after syndactyly reconstruction: associated conditions, prevalence, and preliminary report of a treatment method.

Arshad R Muzaffar1, Francisco Rafols, James Masson, Marybeth Ezaki, Peter R Carter.   

Abstract

PURPOSE: The purpose of this study is 3-fold: to review our cases of keloid formation after syndactyly release, to report a clinical association between primary enlargement of the digits and risk of keloid formation, and to report treatment using low-dose, short-term methotrexate as an adjunct to revision surgery.
METHODS: A retrospective review of patients identified with keloid formation after syndactyly reconstruction showed associated enlargement of the involved digits. A search of medical records for cases in which both syndactyly and digital enlargement occurred was carried out. Charts and images, where available, were reviewed for information about age, gender, involved site, associated conditions, and treatment.
RESULTS: Eight cases of keloids occurred in 1004 surgical procedures in 681 patients carried out during the 20-year period reviewed. Seven patients were white and 1 was Hispanic. Seven of the 8 had associated primary digital enlargement. Two patients who had enlarged syndactylized digits did not develop keloids after surgery. There was no family history in any case. Standard treatment (pressure, topical or intralesional corticosteroids, and re-excision) was unsuccessful in resolving the keloids. Two children treated with adjunctive methotrexate had successful treatment of their keloids and near-normal healing. Length of follow-up time after the last treatment ranged from 6 months to 11 years (average, 5.5 years).
CONCLUSIONS: Primary digital enlargement is highly predictive of risk of keloid formation after syndactyly reconstruction. Very-low-dose, short-term methotrexate was successful as an adjunct to surgical treatment in 2 cases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15043889     DOI: 10.1016/j.jhsa.2003.10.017

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  8 in total

1.  Congenital syndactyly: case by case analysis of 47 patients.

Authors:  Luiz Garcia Mandarano-Filho; Márcio Takey Bezuti; Rubens Akita; Nilton Mazzer; Cláudio Henrique Barbieri
Journal:  Acta Ortop Bras       Date:  2013       Impact factor: 0.513

2.  Methotrexate modulates the expression of MMP-1 and type 1 collagen in dermal fibroblast.

Authors:  Layla Nabai; Ruhangiz T Kilani; Farzian Aminuddin; Yunyuan Li; Aziz Ghahary
Journal:  Mol Cell Biochem       Date:  2015-08-23       Impact factor: 3.396

3.  Scarring in Patients With PIK3CA-Related Overgrowth Syndromes.

Authors:  Jack E Steiner; Catherine E Cottrell; Jenna L Streicher; John N Jensen; David M King; Patricia E Burrows; Dawn H Siegel; Megha M Tollefson; Beth A Drolet; Katherine B Püttgen
Journal:  JAMA Dermatol       Date:  2018-04-01       Impact factor: 10.282

4.  Treatment of common congenital hand conditions.

Authors:  Takashi Oda; Allison G Pushman; Kevin C Chung
Journal:  Plast Reconstr Surg       Date:  2010-09       Impact factor: 4.730

5.  A toe keloid after syndactyly release treated with surgical excision and intralesional steroid injection.

Authors:  Satoko Yamawaki; Motoko Naitoh; Toshihiro Ishiko; Rino Aya; Yasuhiro Katayama; Shigehiko Suzuki
Journal:  Plast Reconstr Surg Glob Open       Date:  2014-08-07

6.  Predictive Factors of Keloid Formation in Congenital Foot Syndactyly.

Authors:  Sang Ho Oh; Sang Hyun Woo
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-11-29

7.  Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly.

Authors:  Jonathan J Rios; Nandina Paria; Dennis K Burns; Bonnie A Israel; Reuel Cornelia; Carol A Wise; Marybeth Ezaki
Journal:  Hum Mol Genet       Date:  2012-10-24       Impact factor: 6.150

8.  Toe keloid after nail extraction treated with surgical excision: A case report.

Authors:  Hao Liu; Kexin Song; Mingzi Zhang; Xinhang Dong; Shu Liu; Youbin Wang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.